Showing results (11-20 of 97) with videos related to
Sort By:
Pageof 10
AIDS Patient Care and Stds|January 24, 2006
Psychometric properties of a lipodystrophy scaleDaniel Lee, Parul Patel, Jennifer Sachs, et al.Journal of Clinical Medicine|November 27, 2024
Reduced Salivary Gustin and Statherin in Long-COVID Cohort with Impaired Bitter TasteHarika Chowdary, Naomi Riley, Parul Patel, et al.Journal of Cataract and Refractive Surgery|July 4, 2006
Topography-guided customized laser-assisted subepithelial keratectomy for the treatment of postkeratoplasty astigmatismMadhavan S Rajan, David P S O'Brart, Parul Patel, et al.Antimicrobial Agents and Chemotherapy|December 21, 2011
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravirIvy Song, Julie Borland, Shuguang Chen, et al.Antiviral Therapy|March 22, 2019
Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjectsSusan L Ford, Yu Lou, Nicole Lewis, et al.The British Journal of Ophthalmology|February 7, 2013
Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconusDavid P S O'Brart, Tsong Q Kwong, Parul Patel, et al.Future Oncology (London, England)|September 25, 2024
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samplesRoss A Soo, Graham Clinthorne, Anu Santhanagopal, et al.Pharmacotherapy|April 5, 2013
Effect of intravenous zanamivir on cardiac repolarizationYu Lou, Jianjun Gan, Amanda Peppercorn, et al.Antimicrobial Agents and Chemotherapy|May 27, 2005
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluidEdmund V Capparelli, Scott L Letendre, Ronald J Ellis, et al.Pharmaceutics|April 26, 2025
Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic ModelingHelen Tracey, Simon T Bate, Susan Ford, et al.Pageof 10